Eesti turba balneoloogiliste kasutamisvõimaluste uuring (II etapp) — Study of Balneological Uses of Estonian Peat (Stage II)
Key Findings
- 7 Estonian peat deposits identified as suitable for balneological use: Hädera, Kõverdama, Larvi, Oese, Parika, Sangla, Törva (Helme)
- Total therapeutic peat reserves: 920,000 tonnes across 378 ha
- Parika deposit: HA 39.30%, HMA 19.32%, FA 1.29% (pure) — highest humic substance content
- Kõverdama: HA 13.77-24.90%, HMA 9.66-16.39%, FA 1.51-2.65% (pure)
- Sangla: HA 19.25%, HMA 3.32-6.44%, FA 0.93-1.54% (pure)
- Hädera: HA 30.12-31.44%, general FA 18.70-20.40%
- Larvi: HA 8.44-20.36%, general FA 18.68-27.70%
- Oese: HA 12.48-20.20%, general FA 19.60-22.80%
- 34 trace elements analyzed in 13 samples — all below hazardous levels in all deposits
- Quality criteria for balneological peat: von Post H6+, water >85%, ash <12%, below bog water table, ecologically clean
- All suitable peat layers are in middle strata of ombrotrophic bogs — most ecologically clean (minimal atmospheric deposition, groundwater, and bedrock contamination)
- Humification 40-50% (von Post 6-8) in all suitable layers
- Collaboration with Finnish Geological Survey (Riitta Korhonen) and University of Tartu Pärnu College (Monika Übner)
Foundational geological survey establishing the existence and chemical composition of Estonian balneological peat reserves. Conducted in collaboration with the Finnish Geological Survey and University of Tartu Pärnu College. Nine peat deposits were initially surveyed; seven met quality criteria. Chemical analyses performed at both the Pärnu College Balneology Laboratory (humic, hymatomelanic, and pure fulvic acids by separate fractionation) and Finnish Biotech OY laboratory (general humic and fulvic acids).
Key finding: Estonian therapeutic peat contains bioactive humic substances up to 60% of organic matter — significantly higher than the Finnish average of 29%. The Parika deposit stands out with 39.30% humic acid and 19.32% hymatomelanic acid. All deposits are ecologically clean, with trace element levels well below Estonian averages and hazardous thresholds.
This report provides the chemical data that later appeared in Orru et al. 2010 and 2011 international publications, and the quality framework that guided the Stage III clinical trials.